Angela Hayes

4.6k total citations
33 papers, 659 citations indexed

About

Angela Hayes is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Angela Hayes has authored 33 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Angela Hayes's work include Cancer-related Molecular Pathways (7 papers), Heat shock proteins research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Angela Hayes is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Heat shock proteins research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Angela Hayes collaborates with scholars based in United Kingdom, United States and Austria. Angela Hayes's co-authors include Florence I. Raynaud, Paul Workman, Bernard Nutley, Ian Collins, G. Wynne Aherne, Kathy Boxall, Michelle D. Garrett, Nicola F. Smith, Suzanne A. Eccles and Melanie Valenti and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Angela Hayes

33 papers receiving 645 citations

Peers

Countries citing papers authored by Angela Hayes

Since Specialization

Citations

This map shows the geographic impact of Angela Hayes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Hayes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Hayes more than expected).

Fields of papers citing papers by Angela Hayes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Hayes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Hayes. The network helps show where Angela Hayes may publish in the future.

Co-authorship network of co-authors of Angela Hayes

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Hayes. A scholar is included among the top collaborators of Angela Hayes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Hayes. Angela Hayes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor 2022 ·European Journal of Cancer ·Paul Workman, Paul A. Clarke, Robert te Poele, Marissa Powers, G. Box, Emmanuel de Billy, (unknown), Albert Hallsworth, Angela Hayes, (unknown), Swee Y. Sharp, Melanie Valenti, Florence I. Raynaud, (unknown), Matthew D. Cheeseman, (unknown)	4
2	A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2 2021 ·Science Advances ·Nicolas Béry, Carole J. R. Bataille, Angela J. Russell, Angela Hayes, Florence I. Raynaud, (unknown), (unknown), (unknown), Ami Miller, Terence H. Rabbitts	11
3	Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds 2021 ·Journal of Immunological Methods ·Peter Canning, Carole J. R. Bataille, Nicolas Béry, (unknown), Angela Hayes, Florence I. Raynaud, Ami Miller, Terence H. Rabbitts	5
4	A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity 2020 ·British Journal of Cancer ·Eleftherios Kostaras, Teresa Kaserer, (unknown), (unknown), (unknown), Pedro Casado, Angela Hayes, Cihangir Yandım, Nicolaos Palaskas, Yi Yu, Brian Schwartz, Florence I. Raynaud, Yuen‐Li Chung, Pedro R. Cutillas, Igor Vivanco	29
5	Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species 2019 ·European Journal of Pharmaceutical Sciences ·(unknown), (unknown), Angela Hayes, Manjuan Liu, (unknown), (unknown), Butrus Atrash, Amir Faisal, Vassilios Bavetsias, Spiros Linardopoulos, Julian Blagg, Florence I. Raynaud	4
6	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases 2019 ·Oncogene ·Chi Zhang, (unknown), May Elbanna, Robin Ketteler, Jamie Freeman, Bissan Al‐Lazikani, Suzanne A. Eccles, Alexis de Haven Brandon, Florence I. Raynaud, Angela Hayes, Paul A. Clarke, Paul Workman, Sibylle Mittnacht	29
7	Synthesis of a benzoxazinthione derivative of tanaproget and pharmacological evaluation for PET imaging of PR expression 2019 ·EJNMMI Radiopharmacy and Chemistry ·Louis Allott, (unknown), Angela Hayes, Florence I. Raynaud, Christopher Cawthorne, Graham Smith	10
8	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs 2012 ·Clinical Cancer Research ·Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, (unknown), Kathy Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John Reader, Louis Chesler, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett	69
9	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors 2011 ·Bioorganic & Medicinal Chemistry ·Stuart C. Wilson, Butrus Atrash, Clare Barlow, (unknown), Peter M. Fischer, Angela Hayes, Lloyd R. Kèlland, Wayne Jackson, Michael Jarman, Amin Mirza, Francisco J. Moreno, Bernard Nutley, Florence I. Raynaud, Peter Sheldrake, Mike Walton, Robert Westwood, Steven R. Whittaker, Paul Workman, Edward McDonald	26
10	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 2010 ·Molecular Cancer Therapeutics ·Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Kathy Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, D. H. Williams, John Reader, Ian Collins, Michelle D. Garrett	63
11	Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements 2010 ·Bioorganic & Medicinal Chemistry ·Jonathan M. Large, (unknown), Florence I. Raynaud, Paul A. Clarke, Angela Hayes, Francesca Di Stefano, Frederique Urban, Stephen J. Shuttleworth, Nahid Saghir, Peter Sheldrake, Paul Workman, Edward McDonald	17
12	The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer 2008 ·Cancer Research ·Adrian Folkes, Stewart Baker, Irina Chuckowree, Suzanne A. Eccles, Angela Hayes, Timothy C. Hancox, (unknown), Alan G. Olivero, Sonal Patel, Giles Pergl-Wilson, Florence I. Raynaud, Anthony G. Robson, Nahid Saghir, Sukhjit Sohal, (unknown), (unknown), Paul Workman, Marketa Zvelebil, Stephen Shuttleworth	5
13	Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620 2008 ·Cancer Research ·Florence I. Raynaud, Angela Hayes, Francesca Di Stefano, Paul A. Clarke, Melanie Valenti, Zahida Ahmad, Sue Eccles, Adrian Folkes, Nahid Saghir, Anthony G. Robson, Stephen Shuttleworth, Paul Workman	1
14	Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors 2006 ·Molecular Cancer Therapeutics ·Nicola F. Smith, Angela Hayes, Karen James, Bernard Nutley, Edward McDonald, Alan T. Henley, Brian Dymock, Martin J. Drysdale, Florence I. Raynaud, Paul Workman	23
15	Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 2005 ·British Journal of Cancer ·Bernard Nutley, Nicola F. Smith, Angela Hayes, Lloyd R. Kèlland, Lisa Brunton, Bernard T. Golding, Graeme C.M. Smith, Niall M.B. Martin, Paul Workman, Florence I. Raynaud	75
16	Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitorR-roscovitine in the mouse 2005 ·Molecular Cancer Therapeutics ·Bernard Nutley, Florence I. Raynaud, Stuart C. Wilson, Peter M. Fischer, Angela Hayes, Phyllis M. Goddard, Steven J. McClue, Michael Jarman, David P. Lane, Paul Workman	25
17	Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone 2004 ·Cancer Research ·Swee Y. Sharp, Alison Maloney, Paul A. Clarke, Wynne Aherne, Suzanne A. Eccles, Kathy Boxall, Martin Rowlands, Florence I. Raynaud, Bernard Nutley, Nicola F. Smith, Angela Hayes, Anthea Hardcastle, Laurence H. Pearl, (unknown), (unknown), (unknown), Thomas P. Matthews, (unknown), Martin J. Drysdale, Paul Workman	1
18	Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice 2004 ·Cancer Chemotherapy and Pharmacology ·Nicola F. Smith, Angela Hayes, Bernard Nutley, Florence I. Raynaud, Paul Workman	12
19	Pharmacokinetic and metabolism studies of a novel synthetic series of heat shock protein 90 (Hsp90) inhibitors 2003 ·Clinical Cancer Research ·(unknown), Angela Hayes, (unknown), Thomas P. Matthews, Bernard Nutley, Thomas S. McDonald, Brian Dymock, Martin J. Drysdale, Florence I. Raynaud, Paul Workman	1
20	The quantitative disposition of procainamide and N-acetylprocainamide in the rat. 1978 ·Journal of Pharmacology and Experimental Therapeutics ·Dennis W. Schneck, Kevin L. Grove, (unknown), (unknown), Angela Hayes	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact